Novartis reports 2014 Q1 sales, profit growth

Novartis reported a 1% increase in net sales to $14 billion in the first quarter of 2014, according to a press release.“Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including [European Union] and U.S. approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero,” Joseph Jimenez, CEO of Novartis, said in the release.

Full Story →